SGS Becomes Medidata Rave Accredited Partner
SGS Life Science Services announced that its Biometrics group became a Medidata Rave accredited partner.
SGS Life Science Services, a pharmaceutical clinical and bioanalytical contract solutions provider, announced that its Biometrics group, one of the largest European data management, statistics and medical writing teams, became a Medidata Rave® accredited partner. Medidata Rave captures, manages and reports clinical research data, designed to help life science companies optimize their research investments, by efficiently streamlining the clinical trial process.
Medidata’s accreditation program for Rave is an in-depth qualification program through both build and process enablement tracks, with the aim for partners to provide end-user training, user and site administration, study build, reporting, outputs and migration services. Implementing Rave studies since 2010, and a Medidata CTMS™ partner for more than five years, SGS Life Science Services has robust and fully optimized processes in place, allowing for short set-up timelines that support the clinical team’s challenge of getting First Patient In (FPI) on time.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
